Nitric oxide-cGMP and prostacyclin-cAMP pathways in patients with type II diabetes and different types of retinopathy

Pathophysiology of Haemostasis and Thrombosis

Volumn 32, Issue 1, 2002, Pages 25-32

  De La Cruz, J P ^a   Moreno, A ^b   Guerrero, A ^a   Ortega, G ^b   Gonzalez Correa, J A ^a   Sanchez De La Cuesta F ^a  

^a UNIVERSITY OF MÁLAGA   (Spain)

^b HOSPITAL UNIVERSITARIO VIRGEN DE LA VICTORIA   (Spain)

Author keywords

Diabetic retinopathy; Endothelial dysfunction; Nitric oxide; Platelets; Prostacyclin

Indexed keywords

6 OXOPROSTAGLANDIN F1 ALPHA; CYCLIC AMP; CYCLIC GMP; NITRIC OXIDE; NITRITE; PROSTACYCLIN;

ADULT; AGED; ARTICLE; CONTROLLED STUDY; ENDOTHELIUM CELL; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; MONOCYTE; NEUTROPHIL; NON INSULIN DEPENDENT DIABETES MELLITUS; PRIORITY JOURNAL; RETINOPATHY; THROMBOCYTE AGGREGATION;

6-KETOPROSTAGLANDIN F1 ALPHA; AGED; CASE-CONTROL STUDIES; CYCLIC AMP; CYCLIC GMP; DIABETES MELLITUS, TYPE 2; DIABETIC RETINOPATHY; EPOPROSTENOL; FEMALE; HUMANS; LEUKOCYTES; MALE; MIDDLE AGED; NEUTROPHILS; NITRIC OXIDE; NITRITES; PLATELET AGGREGATION; PLATELET AGGREGATION INHIBITORS;

EID: 0344118026     PISSN: 14248832     EISSN: None     Source Type: Journal    
DOI: 10.1159/000057285     Document Type: Article

References (34)

1. Brailsford SC, Davies R, Canning C, Roderick PJ: Evaluating policies for the early detection of retinopathy in patients with non-insulin dependent diabetes. Health Care Manag Sci 1998;1:115-124.
2. Klein R, Palta M, Allen C, Shen G, Han DP, D'Alessio DJ: Incidence of retinopathy and associated risk factors from time of diagnosis of insulin-dependent diabetes. Arch Ophthalmol 1997;115:351-356.
3. Reuterving CO, Kratholm J, Wachtmeister L: Ophthalmic health care in diabetes mellitus: A cross-sectional study in northern Sweden. Ophthalmic Epidemiol 1999;6:267-278.
4. Retinopathy and nephropathy in patients with type 1 diabetes four years after a trial of intensive therapy. The Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications Research Group. N Engl J Med 2000;342:381-389.
5. De Vriese AS, Verbeuren TJ, Van de Voorde J, Lameire NH, Vanhoutte PM: Endothelial dysfunction in diabetes. Br J Pharmacol 2000;130: 963-974.
6. Moncada S, Vane JR: Unstable metabolites of arachidonic acid and their role in haemostasis and thrombosis. Br Med Bull 1978;34:129-135.
7. Radomski MW, Moncada S: The biological and pharmacological role of nitric oxide in platelet function. Adv Exp Med Biol 1993;344: 251-264.
8. Michelson AD, Furman MI: Laboratory markers of platelet activation and their clinical significance. Curr Opin Hematol 1999;6:342-348.
9. Knobler H, Savion N, Shenkman B, Kotev-Emeth S, Varon D: Shear-induced platelet adhesion and aggregation on subendothelium are increased in diabetic patients. Thromb Res 1998;90:181-190.
10. Iwase E, Tawata M, Aida K, Ozaki Y, Kume S, Satoh K, Qi R, Onaya T: A cross-sectional evaluation of spontaneous platelet aggregation in relation to complications in patients with type II diabetes mellitus. Metabolism 1998;47:699-705.
11. Roshan B, Tofler GH, Weinrauch LA, Gleason RE, Keough JA, Lipinska I, Lee AT, Delia JA: Improved glycemic control and platelet function abnormalities in diabetic patients with microvascular disease. Metabolism 2000;49:88-91.
12. Mazzanti L, Mutus B: Diabetes-induced alterations in platelet metabolism. Clin Biochem 1997;30:509-515.
13. De La Cruz JP, Moreno A, Sintas A, García Campos JM, Sánchez de la Cuesta F: Platelet hyperaggregation in diabetic patients with different types of retinopathy is partially influenced by erythrocytes in whole blood. Diabetes Res 1997;32:51-68.
14. De La Cruz JP, Moreno A, Guerrero A, Sán-chez de la Cuesta F: Antiplatelet effects of prostacyclin and nitric oxide in patients with type I diabetes and ischemic or edematous retinopathy. Platelets 2001;12:210-217.
15. Cardinal DC, Flower RJ: The electronic aggregometer: A novel device for assessing platelet behavior in blood. J Pharmacol Methods 1980; 3:135-158.
16. Gasser JA, Cooper MB, Tan KC, Saggerson ED, Betteridge DJ: Altered cellular signalling and decreased platelet sensitivity to adenosine in insulin-dependent diabetic patients with proliferative retinopathy. Cell Signal 1993;5: 145-153.
17. Mendez JD, Zarzoza E: Inhibition of platelet aggregation by L-arginine and polyamines in alloxan treated rats. Biochem Mol Biol Int 1997;43:311-318.
18. Huszka M, Kaplar M, Rejto L, Tornai I, Palatka K, Laszlo P, Udvardy M: The association of reduced endothelium derived relaxing factor-NO production with endothelial damage and increased in vivo platelet activation in patients with diabetes mellitus. Thromb Res 1997;86: 173-180.
19. Ferlito S, Gallina M: Nitrite plasma levels in type 1 and 2 diabetics with and without complications. Panminerva Med 1998;40:304-308.
20. Martina V, Bruno GA, Trucco F, Zumpano E, Tagliabue M, Di Bisceglie C, Pescarmona G: Platelet cNOS activity is reduced in patients with IDDM and NIDDM. Thromb Haemost 1998;79:520-522.
21. Rabini RA, Staffolani R, Fumelli P, Mutus B, Curatola G, Mazzanti L: Decreased nitric oxide synthase activity in platelets from IDDM and NIDDM patients. Diabetologia 1998;41: 101-104.
22. Pitei DL, Watkins PJ, Edmonds ME: NO-dependent smooth muscle vasodilation is reduced in NIDDM patients with peripheral sensory neuropathy. Diabet Med 1997;14:284-290.
23. Michimata T, Murakami M, Iriuchijima T: Nitric oxide-dependent soluble guanylate cyclase activity is decreased in platelets from male NIDDM patients. Life Sci 1996;59:1463-1471.
24. West IC: Radicals and oxidative stress in diabetes. Diabet Med 2000;17:171-180.
25. Bonnefont-Rousselot D, Bastard JP, Jaudon MC, Delattre J: Consequences of the diabetic status on the oxidant/antioxidant balance. Diabetes Metab 2000;26:163-176.
26. Moncada S, Palmer RM, Higgs EA: Nitric oxide: Physiology, pathophysiology, and pharmacology. Pharmacol Rev 1991;43:109-142.
27. Moro MA, Darley-Usmar VM, Goodwin DA, Read NG, Zamora R, Feelisch M, Radomski MW, Moncada S: Paradoxical fate and biological action of peroxynitrite on human platelets. Proc Natl Acad Sci USA 1994;91:6702-6706.
28. Brown AS, Moro MA, Masse JM, Cramer EM, Radomski MW, Darley-Usmar V: Nitric oxide-dependent and independent effects on human platelets treated with peroxynitrite. Cardiovasc Res 1998;40:380-388.
29. Tannous M, Rabini RA, Vignini A, Moretti N, Fumelli P, Zielinski B, Mazzanti L, Mutus B: Evidence for iNOS-dependent peroxynitrite production in diabetic platelets. Diabetologia 1999;42:539-544.
30. Zou M-H, Bachschmid M: Hypoxia-reoxygenation triggers coronary vasospasm in isolated bovine coronary arteries via tyrosine nitration of prostacyclin synthase. J Exp Med 1999;190: 135-139.
31. Moreno A, De La Cruz JP, García Campos J, Sánchez de la Cuesta F: Prostacyclin-thromboxane balance and retinal vascular pattern in rats with experimentally induced diabetes. Can J Ophthalmol 1995;30:117-123.
32. De La Cruz JP, Moreno A, Sánchez de la Cuesta F, García Campos J: Effect of antiplatelet drug therapy on the retinal vascular pattern in experimental diabetes. Can J Ophthalmol 1990;25:329-332.
33. De La Cruz JP, Moreno A, Muñoz M, García Campos J, Sánchez de la Cuesta F: Effect of aspirin plus dipyridamole on the retinal vascular pattern in experimental diabetes mellitus. J Pharmacol Exp Ther 1997;280:454-459.
34. Moreno A, De La Cruz JP, Mérida F, García Campos JM, Sánchez de la Cuesta F: Effects of ditazol on the vascular retinal pattern in experimental diabetes in rats. Haemostasis 1995;25: 166-171.